Gotistobart clinical trials

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.